HPLC method for monitoring SDZ PSC 833 in whole blood

Clinical Chemistry

Volumn 43, Issue 3, 1997, Pages 505-510

  Scott, Mitchell G ^a   Hock, Karl G ^a   Crimmins, Daniel L ^a   Fracasso, Paula M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cyclosporine; multidrug resistance; P glycoprotein

Indexed keywords

VALSPODAR;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG SCREENING; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MULTIDRUG RESISTANCE;

EID: 0031043399     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/43.3.505     Document Type: Article

References (23)

1. Van der Bliek AM, Borst P. Multidrug resistance. Adv Cancer Res 1989;52:165-203.
2. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol 1992;12:243-53.
3. Pinedo HM, Giacone G. P-glycoprotein - a marker of cancer cell behavior. N Engl J Med 1993;333:1417-9.
4. Roninson I. The role of MDR1 (P-glycoprotein) gene in multidrug resistance in human cancer. Crit Rev Oncol Hematol 1992;43:95-102.
5. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume regulated chloride channels associated with the human multidrug resistance P-glycoprotein. Nature 1992;355:830-3.
6. Tsuruo T, Iida H, Tsukagosti S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
7. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
8. Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporine-A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4.
9. Sonneveld P, Durie BGM, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet 1992;340:255-9.
10. Twentyman PR. Cyclosporines as drug resistance modifiers. Biochem Pharmacol 1992;43:109-117.
11. Myers BD, Ross J, Neurton L, Luetscher J, Perlroth M. Cyclosporine associated chronic nephropathy. N Eng J Med 1984;311: 699-705.
12. Kahan BD, Flechner SM, Lorber MI, Jensen C, Golden D, Van Buren CT. Complications of cyclosporine therapy. World J Surgery 1986;10:348.
13. Gaveriaux C, Boesch D, Jackez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporine analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991; 2:225-34.
14. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 1991;196:26-32.
15. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 1991;27:1639-42.
16. Keller RP, Altermatt HJ, Nooter K, et al. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992;50:593-7.
17. Sandoz Research Institute, Sandoz Pharmaceuticals Corporation. SDZ PSC 833 Investigator's Brochure, East Hanover, NJ, September 1994.
18. Vine W, Bowers LD. Cyclosporine: structure, pharmacokinetics and therapeutic drug monitoring. CRC Crit Rev Clin Lab Sci 1987;25:275-311.
19. Holt DW, Johnston A, Roberts NB, Tredjer JM, Trull AK. Methodological and clinical aspects of cyclosporine monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994;31:420-46.
20. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990;36:1969-73.
21. Bowers LD, Matthews SE. Investigation of the mechanism of peak broadening observed in the high-performance liquid chromatography analysis of cyclosporine. J Chromatogr 1985;333:231-8.
22. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method-comparison analysis. Clin Chem 1979;25: 432-8.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.